|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2021-09-27 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2021-08-23 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2015-10-21 |
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients with Hyperphosphataemia
PA21咀嚼片和碳酸司维拉姆用于治疗中国CKD患者高磷血症的安全性和有效性的Ⅲ期研究
该临床研究的目的是通过与碳酸司维拉姆比较,评估PA21在中国成年维持性透析的CKD受试者中降低血清磷方面的安全性和有效性
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients with Hyperphosphataemia
100 项与 Vifor Fresenius Medical Care Renal Pharma France S.A.S. 相关的临床结果
0 项与 Vifor Fresenius Medical Care Renal Pharma France S.A.S. 相关的专利(医药)
100 项与 Vifor Fresenius Medical Care Renal Pharma France S.A.S. 相关的药物交易
100 项与 Vifor Fresenius Medical Care Renal Pharma France S.A.S. 相关的转化医学